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ABSTRACT
Objective: The objective of this report is to provide, in
detail, the evidentiary requirements contained in Version
2.0 of the Academy of Managed Care Pharmacy’s
(AMCP’s) Format for Formulary Submissions and to elab-
orate on several key issues regarding the use of the Format
that users, potential users, and pharmaceutical manufac-
turers have raised since AMCP published the ﬁrst version
of the guidelines in October 2000.
Background: The AMCP published its Format for For-
mulary Submissions in October 2000. The AMCP lead-
ership and its members were motivated to develop these
guidelines by a growing need to ensure that any increased
utilization of medications, biopharmaceuticals, and vac-
cine products was appropriate and that newer products
would bring added clinical and economic value to covered
populations. Since publication of the Format, it has
garnered nationwide publicity and attracted consider-
able positive and negative attention. As adoption of the
AMCP Format has spread, manufacturers have begun to
standardize the framework within which they present
population-speciﬁc data. Since publication of the AMCP
Format, the AMCP and the Foundation for Managed
Care Pharmacy (FMCP) have continuously sought input
from pharmaceutical manufacturers and health-system
pharmacists through various venues to improve and
clarify the process. Version 2.0 is the ﬁrst attempt to
address user’s comments and concerns.
Methods: The majority of the article text is taken directly
from Version 2.0 of the AMCP Format for Formulary
Submissions published by the AMCP in October 2002.
Conclusion: The AMCP and the FMCP believe that the
AMCP Format is a tool that will help health systems
establish a record of commitment to rational decision
making, thus gaining the conﬁdence of patients, clini-
cians, and members. While providing manufacturers a
vehicle for communicating the scientiﬁcally based value
of their product to a health system, the required evi-
dence to substantiate that value argument allows a
pharmacy and therapeutics committee to determine the
clinical beneﬁts of a drug, verify any cost savings the
drug may generate, and determine the overall cost con-
sequences to their health system. The AMCP Format for
Formulary Submissions is an essential tool to evaluate
medications, but requires thoughtful consideration as it
is used.
Keywords: cost-effectiveness, drug costs, evidence-based
medicine, format, formulary, formulary guidelines, for-
mulary submissions, guidelines.
Introduction: Foundation of a Sound 
Formulary System
Rational product adoption decisions employing
clinical, economic, and humanistic data are built on
the foundation of a sound formulary system. Newly
approved pharmaceutical, biological, and vaccine
products should be subjected to a rigorous clinical
review and periodic re-review, based on evidence
from the clinical literature. Evidence-based assess-
ment of product efﬁcacy, safety, effectiveness, and
cost-effectiveness provide the foundation for such a
review. These precepts are afﬁrmed by the National
Committee for Quality Assurance managed-care
organization accreditation standard “Procedures
for Pharmaceutical Management” and by the “Prin-
ciples of a Sound Drug Formulary System” devel-
oped and endorsed in August 2000 by the Academy
of Managed Care Pharmacy (AMCP) and the Alli-
ance of Community Health Plans, the American
Medical Association, the American Society of
Health-System Pharmacists, the Department of Vet-
erans Affairs, the Pharmacy Beneﬁt Management
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Strategic Healthcare Group, the National Business
Coalition on Health, and the U.S. Pharmacopeia
[1].
The goal of the formulary review process is to
provide a quality pharmaceutical beneﬁt, deter-
mined through an evidence-based decision-making
process, taking into account the reality of con-
strained health-care budgets. Where feasible, health
systems should make product comparisons relative
to existing competitor products as well as to pla-
cebo. For products with similar safety and efﬁcacy
proﬁles, they may reasonably make such decisions
primarily on net acquisition cost, unless manufac-
turers can support reasonable product value or
other program efﬁciency arguments with pharmaco-
economic evidence. Cost considerations, in certain
circumstances, may be relevant reasons for limiting
patient access to certain products. Nevertheless,
practices, such as prior authorization, closed formu-
laries, or placing all high-cost products in the high-
est copayment tier, tend to be highly controversial
and are often contested. A brief glossary of terms
can be found in Appendix 1.
Guidelines and Drug Coverage Decisions
Health-care professionals and health-care systems
worldwide are challenged daily to set priorities in
an environment where demand for health-care serv-
ices outweighs the supply of resources allocated to
ﬁnance it. In the absence of widely accepted models
for legitimate and fair priority setting in health care,
health-care professionals must rely on the best
available evidence to reach consensus about what
constitutes a fair allocation of resources to meet
competing health-care needs. For example, health-
care systems frequently conduct formulary decision
making under uncertain conditions owing to the
variability of available evidence on safety, effective-
ness, and appropriateness of particular interven-
tions. Gibson et al. [2] state, “In the absence of
consensus on guiding principles, the problem of pri-
ority-setting becomes one of procedural justice—
legitimate institutions using fair processes.” There-
fore, health systems need tools to support product
evaluation and selection with clinical outcomes as
the most important consideration, while avoiding
the use of low acquisition cost and rebates as the
primary basis for selection.
Australia and some European countries have
used guidelines requiring pharmaceutical manufac-
turers to include detailed clinical outcomes and
health economic information as part of a formu-
lary submission process since the very early 1990s,
and Gold et al. [3] have provided methodologic
guidelines for researchers who conduct cost-
effectiveness studies. In 1996, Langley and Sullivan
proposed a set of guidelines for use by health care
systems in the U.S. to obtain useful, comparative,
clinical information and economic analysis on
pharmaceutical products in order to make sound
drug purchasing decisions [4]. Nevertheless, with
the exception of guidelines developed by The
Regence Group in the United States in 1994, and
substantially revised in 1998 [5], no standardized
format for the submission of product clinical and
economic information by manufacturers existed in
America. In an attempt to ﬁll this vacuum, the
AMCP published the AMCP Format for Formulary
Submissions in October 2000. The AMCP leader-
ship and its members were motivated to develop
these guidelines by a growing need to ensure that
any increased utilization of medications, biophar-
maceuticals, and vaccine products was appropriate
and that newer products would bring added clini-
cal and economic value to covered populations. To
satisfy this need, the Academy recognized that it
had to provide its members with the means to: 1)
promote the concept of combining efﬁcacy, safety,
effectiveness, and economic evaluation for the
formulary decision-making process; 2) provide a
consistent and direct means for manufacturers to
supply information directly to health systems to
support use of their products; and 3) break down
cost silos and emphasize that simple acquisition
cost reduction is not the best approach to control-
ling overall health-care expenditures.
Since initial publication of the AMCP Format
[6], the Foundation for Managed Care Pharmacy
(FMCP) has spearheaded several initiatives to pro-
mote its usage. These efforts have included presen-
tations and forums at AMCP and other professional
organizations’ national meetings and conferences,
articles in newsletters, peer-reviewed and lay liter-
ature, and numerous seminars designed to train
health-system pharmacists and pharmaceutical
industry personnel on the appropriate use of the
Format. Consequently, the AMCP Format has gar-
nered nationwide publicity and attracted consider-
able attention. Adoption of the AMCP Format
process by health systems and the pharmaceutical
industry has exceeded the AMCP’s and the FMCP’s
expectations. Over the past 2 years, a growing
grassroots network has developed among health
systems stimulating adoption initially by managed
health-care systems and pharmacy beneﬁt manage-
ment company (PBM) and, most recently, by hospi-
tals, integrated health-care systems, state Medicaid
agencies, and the Department of Defense. As adop-
tion of the AMCP Format has spread, manufactur-
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ers have begun to standardize the framework within
which they present population-speciﬁc data.
Version 2.0 of the AMCP Format, approved by
the AMCP Board of Directors and released in Octo-
ber 2002, is part of an ongoing attempt to issue con-
temporary standards for evidentiary requirements
and to address user comments and concerns. Cur-
rent and potential users of the AMCP Format will
ﬁnd that the contents sections of the guidelines have
not changed substantially. Revision efforts in these
sections were focused on providing additional clar-
ity and making the document more user-friendly
and understandable. A companion document ad-
dresses major areas of concern expressed by health-
system pharmacists and the pharmaceutical
industry over the past 2 years [7].
The Role of the Format
Formulary submission guidelines support the
informed selection of pharmaceuticals, biologicals,
and vaccines by standardizing and communicating
product and supporting program information
requirements, projecting their impact on both the
organization and its enrolled patient population,
and making evidence and rationale supporting all
choice(s) clearer and evaluable by the health-system
decision makers. These guidelines emphasize that,
whereas cost–beneﬁt analysis and economic mode-
ling are important elements in the value equation,
they are secondary to the principal clinical concerns
of safety and efﬁcacy.
The AMCP Format’s process is designed to main-
tain a high standard of objectivity to achieve two
important goals. First, it is intended to improve the
timeliness, scope, quality, and relevance of informa-
tion available to a health system’s evaluators and
ultimately to its pharmacy and therapeutics (P & T)
committees. Nevertheless, health systems should
not expect that its use would necessarily improve
outcomes or lower drug expenditures. A distin-
guishing feature of the AMCP Format is its use as
an unsolicited request from a health system to a
manufacturer for all possible clinical and economic
information necessary to assess the overall clinical
utility and value that a product brings to a speciﬁc
patient population and health-care system. In
response to this unsolicited request, manufacturers
are asked to submit all possible published and
unpublished studies and information regarding
both Food and Drug Administration (FDA)-
approved indications and anticipated off-label uses
of the product (permitted under Section 114(a) of
the Food and Drug Administration Modernization
Act of 1997), should such information exist [8].
Therefore, this request attempts to improve access
to material that has been difﬁcult to obtain in the
past. It also enables manufacturers to submit such
data within regulatory constraints mandated by the
FDA. Whereas no explicit FDA guidance regard-
ing unsolicited requests exists, FDA ofﬁcials have
repeatedly stated their intention to issue such guid-
ance in the future. In the meantime, FDA ofﬁcials
have very clearly stated their position that they have
responsibility for: 1) assuring that requests for off-
label product information are truly unsolicited and
unprompted; 2) assuring that the information pro-
vided is not false and misleading; and 3) assuring
that the response is speciﬁc to the requestor.
Further, by assessing the health-system impact of
using a product, the data requested can improve the
P & T committee’s ability to assess the effects of for-
mulary alternatives on clinical outcomes and eco-
nomic consequences for the entire health system.
Nevertheless, this information still must be weighed
in the context of other values such as equity, social
justice, the health of individuals as against commu-
nities, the “rule of rescue,” and democratic decision
making [2,9,10].
Second, the AMCP Format streamlines the data
acquisition and review process for health-system
staff pharmacists. By clearly specifying the stand-
ards of evidence implicit in the existing formulary
process, the submission guidelines furnish pharma-
ceutical manufacturers with consistent direction
concerning the nature and format of information
that is expected. In addition, the standardized for-
mat allows clinical staff to formally evaluate the
completeness of submissions received and to easily
add the results of the health system’s own literature
reviews and analysis. Manufacturers should under-
stand that submission of information in the format
recommended does not guarantee approval of their
product for formulary listing. Manufacturers and
health systems should view discussion about, and
subsequent submission of, a dossier, as a process to
improve the quality and layout of information pro-
vided, but not as a formula for approval. The guide-
lines offer a clear, shared vision of the requirements
to facilitate the collaboration necessary between
health systems and manufacturers to support drug
product evaluation. Recognizing that manufactur-
ers may not have all the requested information,
especially for new products, the document describes
the minimum information requirements necessary
to support a comprehensive assessment of the pro-
posed product.
In response to similar requirements for reim-
bursement, pricing, and formulary listing in
Australia, Canada, the United Kingdom, and other
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countries, pharmaceutical manufacturers are
already submitting comprehensive reports on the
effectiveness, safety, and cost impact of their pro-
ducts [11–14]. The AMCP Format’s requirements
mirror these requests by requiring manufacturers
to provide product dossiers that contain sufﬁcient
detail to give transparency to the analytical meth-
ods. Although the Format suggests a formalized sys-
tem, users should view it as a dynamic, rather than
static, process. The AMCP and FMCP anticipate
that increased standardization of information will
lead to progressive improvement in the quality of
submissions over time and provide health-system
pharmacists with data often unavailable in the past.
The AMCP is not a standard-setting organiza-
tion. Therefore, the Academy has always viewed the
AMCP Format as a template or guide, not a man-
date or standard. As such, it does not claim to es-
tablish a standard of practice for managed-care
pharmacy. It is up to individual health-care systems
to decide how they will implement the AMCP For-
mat and how they will operate their formulary
review processes. For example, a health system may
require dossiers for only new molecular entities.
Another may require dossiers for all new products
at launch time and for existing products through
their annual therapeutic class reviews. Others may
choose to provide exceptions to the submission
requirements for certain drug classes such as orphan
drug products, chemotherapy agents, and HIV/
AIDS drugs. Ideally, health systems should only
consider products for formulary review when the
manufacturer can submit a complete dossier. Real-
istically, following an unsolicited request from a
health system, manufacturers should make every
attempt to submit a complete dossier. When evi-
dence is missing, the manufacturer should provide
the health system with a detailed explanation of
what evidence is missing and a plan that addresses
this deﬁciency within a speciﬁc time limit. If a dos-
sier is not submitted following a health system’s
unsolicited request, the health system should reserve
the right either to refuse to consider the product for
formulary admission or to exercise other available
options regarding the product’s beneﬁt status that
are in keeping with its formulary and drug beneﬁt
management policies and procedures.
Role of the Health System
Successful implementation of the AMCP Format
process by a health system will include: human,
technical (IT), and ﬁnancial resources to support the
process within the plan including support of senior
management and the P & T committee; a com-
mitment by all staff to make it work; clear com-
munication of AMCP Format requirements to
pharmaceutical industry representatives; health-
system pharmacy staff trained to interpret and inte-
grate the data presented into the formulary process;
and accessibility to health-system staff by industry
representatives for presentations on data and eco-
nomic models.
In addition, the health system should provide
the manufacturer with timely information regard-
ing dossier submission and product evaluation
such as a dossier submission deadline; anticipated
date of initial product review or re-evaluation;
general demographic information to assist in
development of economic analyses, if feasible; noti-
ﬁcation of additional information or data clariﬁca-
tion requirements; and the P & T Committee’s
recommendation.
The Manufacturer’s Role
Using the AMCP Format, the pharmaceutical indus-
try will have the opportunity to justify the price of
a new agent in terms of its overall value to the
health system. In addition, industry scientists and
consultants, using a reasonable scientiﬁc frame-
work, will have the opportunity to provide addi-
tional information (e.g., adherence data, patient
satisfaction, indirect and nonmedical cost impacts)
to demonstrate the broad value of their products
when compared to usual treatments. Therefore,
manufacturers have increased responsibility for
providing relevant clinical data and economic
impact information. The economic data requested
must be broadly applicable to a health system’s pop-
ulation and address the systemwide impact of
formulary changes on both clinical outcomes and
resource utilization and costs. Early planning by
manufacturers will help ensure that their product
value message is supported by credible evidence.
Therefore, it is vital that manufacturers begin a rig-
orous planning process for drug dossier develop-
ment during the early stages of Phase III trials. The
AMCP Format does not specify methods for eco-
nomic evaluation. It is the submitter’s responsibility
to utilize appropriate techniques and data sources.
Manufacturers should complete their formulary
submission dossiers using this AMCP Format to
integrate the relevant published and unpublished
data evaluating the efﬁcacy, safety, economic
impact, and other medical outcomes associated
with the use of their product. They should also
complete and present Sections 1 through 4 of the
The AMCP Format: An Evolving Standard 509
Format’s Evidentiary Requirements in the order
listed. Compliance with this reporting format
allows for efﬁcient review and facilitates the use of
provided information by decision makers. Marked
deviations from the AMCP Format may delay the
review process. As stated previously, dossiers must
provide sufﬁcient detail to give transparency to the
analytical methods used; however, the AMCP
Format provides considerable ﬂexibility. Where spe-
ciﬁc sections or data are unavailable or incomplete,
the manufacturer should identify the missing data,
explain why it is missing, and explain when it will
be supplied, if at all. Manufacturers should provide
the following additional information: a comprehen-
sive list of references for all studies cited and for
information sources from which they drew esti-
mates for use in the economic evaluation; the iden-
tity of and contact information for author(s) of the
submission document; identity of the author(s) of
primary economic evaluations conducted for clini-
cal and disease management intervention strategies;
and the identity of a contact person who can answer
questions and provide additional information re-
garding the submission materials for the health-
system reviewers.
The Conﬁdentiality Issue
Pharmaceutical companies have repeatedly ex-
pressed concern over the ability of health systems
to keep proprietary portions of their product dossi-
ers, such as the economic model, conﬁdential. The
AMCP has always supported the desire by the phar-
maceutical industry to maintain the conﬁdentiality
of certain information contained in product dossi-
ers. The most recent version of the AMCP Format
contains the following statement: “By submitting
this request (the health system) recognizes that con-
ﬁdential information may be provided. (The health
system) recognizes the need to respect and honor
commercial-in-conﬁdence information and may be
willing to sign necessary conﬁdentiality agreements
under agreed circumstances.” As public agencies
such as state Medicaid agencies and the Department
of Defense have begun to adopt the AMCP Format,
some pharmaceutical companies have expressed an
increasing level of concern about the need for con-
ﬁdentiality. The Academy has counseled public
agencies that are considering the use of the AMCP
Format to develop procedures that will allow them
to keep the dossiers conﬁdential. The Academy
strongly recommends that any organization that is
using AMCP’s Format should work diligently to
ﬁnd ways to keep the dossiers conﬁdential and
examine all opportunities to work within state stat-
utes in meeting this goal. If issues of conﬁdentiality
cannot be overcome because of state public disclo-
sure statutes, the information provided by a phar-
maceutical manufacturer may not contain sufﬁcient
evidence for a public agency to make a rational
evidence-based decision regarding the value of
the product under consideration. In addition, the
AMCP encourages any organization that begins
using AMCP’s Format hold the presubmission meet-
ing with pharmaceutical companies called for in the
AMCP Format to disclose the level of conﬁdential-
ity that will be possible and to ascertain what level
of data can be expected to be furnished.
In supporting this concern, it is important to
point out that this issue is unique to the United
States, because product evaluations are available to
the public in Canada, the United Kingdom, and
Australia [15]. The concerns in this country seem to
revolve around the pharmacoeconomic model, the
submission of unpublished studies, and off-label use
information and the creation of the dossier itself.
While some pharmaceutical companies have spent a
great deal of time and money on outcomes research,
pharmacoeconomic modeling, and creation of dos-
siers, others are not as scientiﬁcally sophisticated.
Because of this broad variation, some pharma-
ceutical companies would like to keep their work
conﬁdential to prevent their competitors from capi-
talizing on their efforts [7].
Communication: The Key to Success
There should be substantial ongoing communica-
tion between the health system and the phar-
maceutical company throughout the formulary
submission process to manage expectations and
maximize the quality of the deliverables. Those
organizations that have been early adopters of the
AMCP Format have expressed the importance of
and concern for good communication. The most
common element in the majority of project failures,
whether it is from employee performance, the busi-
ness plan, or vendor relationships, is communica-
tion. When a dossier is requested from a health
system, it is important for that organization to
explain to the pharmaceutical company some basic
information, such as their timeline, the evaluation
process, potential data sources, any special needs
that might exist, etc. This also gives the pharma-
ceutical company an opportunity to discuss deliv-
erables. If they cannot submit speciﬁc studies or
provide a certain piece of the economic analysis, it
is better to understand the limitations up front.
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Again, the AMCP does not presume to dictate to its
members that they should signiﬁcantly alter or
disrupt their normal lines of communication with
pharmaceutical manufacturers. Nevertheless, both
parties should recognize that when there is a high
level of collaboration, there is a relative increase in
the chances that the process will be smoother and
the quality of the dossiers submitted will be higher
[7].
Dialogue with the FDA
Because the FDA closely regulates the information
a pharmaceutical company can provide regarding
their medications, there is apprehension that
complying with the AMCP Format information
requirements may raise concerns at the FDA.
Beginning long before the AMCP Format’s publica-
tion, the Academy has maintained an ongoing dia-
logue with the FDA to keep them apprised of the
project’s progress and to seek their guidance. FDA
ofﬁcials have stated on several occasions that they
are comfortable with the Academy’s position that
the AMCP Format represents an unsolicited re-
quest from a health system to a pharmaceutical
company for all possible published and unpub-
lished studies and information regarding both
FDA-approved indications and anticipated off-
label uses of the product. As mentioned earlier, the
FDA has three areas of concern relative to this
process. First, the information provided cannot be
false or misleading. Second, the request must truly
be unsolicited. Third, the response must be speciﬁc
to the requestor.
Regarding the ﬁrst concern, FDA regulations
require pharmaceutical companies to provide accu-
rate information that will beneﬁt the requestor. The
pharmaceutical industry takes this responsibility
seriously, and the AMCP Format recognizes the
importance of these requirements. Health systems
and manufacturers can virtually eliminate the sec-
ond and third concerns if they follow some simple
procedures. Health systems must initiate the request
and clearly identify the information they desire. The
AMCP Format is a template designed speciﬁcally
for this purpose. The AMCP recommends that
health systems also submit a signed request letter to
accompany the AMCP Format. Pharmaceutical
companies must refrain from taking any proactive
steps that could be construed as marketing and
promotion, such as preparing identical formulary
submission documents (dossiers) for a product with
the intent of soliciting health-system pharmacist’s
requests for the dossiers. In this scenario, the
request would not be truly unsolicited nor would
the contents of the response (the dossier) be speciﬁc
to the requestor [7].
Customizing the Economic Model
Some health-care system P & T committee members
are under the impression that only pharmacoeco-
nomic models that strictly mirror a health system’s
targeted patient population are acceptable. The
AMCP Format describes in some detail the most
important elements of the requested pharmacoeco-
nomic model. The AMCP Format further stipulates
that the economic data called for must be broadly
applicable to a health system’s population address-
ing the systemwide impact of formulary changes
on both clinical outcomes and resource utilization
and costs. The AMCP Format, however, does not
specify methods for economic evaluation. It is
the submitter’s responsibility to utilize appropriate
techniques and data sources. Ideally, a manu-
facturer would use a health system’s own data to
customize the model. Realistically, a highly individ-
ualized model may not be necessary, feasible, or
scientiﬁcally plausible. Often, the information nec-
essary to create a highly individualized model will
not be available because health systems will be
either unwilling or unable to supply it. A reasonable
compromise may be for the health system to request
a model based on national norms or a pre-existing
model with the manufacturer justifying the rele-
vance of the data to the health system’s patient
population. In addition, the model should be trans-
parent and adaptable, allowing the health system to
change multiple elements by inserting its own data.
Once a manufacturer receives an unsolicited request
letter, it can facilitate this process and avoid misun-
derstandings by asking the health system to answer
a standard set of questions that would detail the
information they would be willing to accept, such as
national norm data or a pre-existing model. A man-
ufacturer’s dossier that meets a health system’s
criteria is more likely to conform to the FDA’s
requirements for responses to unsolicited requests
[7].
The Importance of Clinical Information
A misconception that has been percolating among
potential users of the AMCP Format is that it is
merely a tool for presentation of a pharmacoeco-
nomic model. Consequently, health systems that
have little expertise in appraising economic models
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initially shied away from adopting the guidelines. A
careful examination of the AMCP Format docu-
ment will clearly show that the these guidelines, ﬁrst
and foremost, require the health-system staff to per-
form a thorough clinical evaluation of the medica-
tion based on all possible available information
obtained from the manufacturer and other sources.
If the desired outcome of the medication is not sig-
niﬁcant or the side effects too onerous, an economic
review would be unnecessary. It is imperative to
determine the potential clinical impact of a drug on
its target patient population before considering the
economic consequences.
The ﬁeld of pharmacoeconomics is relatively
new. Therefore, the current number of individuals
in this country with a great deal of knowledge and
experience in analyzing the type of information
required by the AMCP Format is limited. While
pharmacoeconomic models and outcomes research
have become increasingly accepted as tools for help-
ing health-care systems make formulary decisions,
many health systems do not have a pharmacist on
staff with sufﬁcient experience to analyze this infor-
mation. There are at least two solutions to this
problem. One would be to acquire pharmacoeco-
nomics training for one or two staff pharmacists.
Numerous organizations around the country pro-
vide this type of training, including the FMCP.
Another solution is to hire an outside consultant to
perform the reviews on the pharmacoeconomic
modeling. Private consultants, faculty at colleges of
pharmacy and experts in the public health arena can
help meet health systems’ needs [7].
The Formulary Submission Process
Content
The AMCP Format guidelines do not restrict the
content, presentation of data, and the research
methods of studies that comprise the dossier.
Rather, they specify evidentiary requirements for
product review. Nevertheless, in preparation of the
evidence, the approach and method adopted by the
manufacturer and the techniques employed should
be consistent with the formulary evaluation objec-
tives of the health system. The guidelines strongly
recommended that the manufacturer consult with
the health system’s representatives to determine
appropriate sources for data and to agree on speciﬁc
requirements and model assumptions (Table 1).
Standards of Care and Data Sources
Manufacturers design clinical development pro-
grams, in large part, to meet regulatory require-
ments. When feasible, manufacturers should
consider the broader clinical and payer audience
who require evidence on new drugs. For example,
manufacturers might modify trial designs to reﬂect
comparison products of interest to health systems.
Furthermore, economic evaluations should be capa-
ble of reﬂecting the characteristics of the treatment
environment of the health system. Analyses based
on clinical trials alone or data from other health sys-
tems or PBMs may be insufﬁcient unless the manu-
facturer shows them to be directly applicable to
the health system’s membership. The manufacturer
should focus on patterns of medical services pro-
Table 1 Agenda for presubmission meeting
A presubmission meeting(s) should take place at least 4 to 6 months before the actual date of anticipated product review to allow time for a 
manufacturer to gather the necessary data. The meeting(s) will also serve as a forum to discuss the consequences of missing information 
deemed necessary by the health system. This agenda can serve as a discussion guide to ensure that the health system and the manufacturer 
address relevant topics. Ongoing communications should occur as deemed necessary.
Manufacturer representatives should provide a copy of, and be prepared to discuss, the following at the ﬁrst meeting(s):
a. List of intended indications.
b. Summary of studies to be included in the formulary submission.  This will include:
• Clinical trials (experimental and nonexperimental)
• Outcomes studies
• Meta-analysis
• Retrospective studies
• Economic and budget impact models
c. Use of comparator products and their appropriateness.
d. A general description of how the cost and outcomes impact assessments will be developed. 
This should include
• List of data sources (studies, databases, etc.)
• Discuss incorporation of health-system data
• Discuss conversion of efﬁcacy to effectiveness for both drug and comparators
• Approach to modeling the health system’s health-care environment
• Discuss level of patient switching and impact on overall costs
• Assumptions and suggested approach for determining patient characteristics for switching
e. Summary of anticipated studies to be completed within 1–3 years.
f.  A completed submission checklist (see Table 10).
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vided directly by reasonable peer organizations. In
some cases, there may be differences of opinion as
to what constitutes appropriate standards of care.
This should be resolved with the health system
before submission.
Disclosure of Potential Reporting Bias
To minimize the potential for bias in formulary sub-
missions, manufacturers should follow generally
accepted rules of scientiﬁc conduct and reporting of
clinical and economic evaluation data [16,17]. At a
minimum, the following should be disclosed for
economic evaluation studies, budget impact models,
and authors of the submission dossier: the identity
of all investigators/authors and the details of their
afﬁliations and all ﬁnancial or contractual relations
that might inﬂuence the independence of the inves-
tigators/authors.
Recommended Formulary Submission 
Timeline and Procedures
New Products
The AMCP Format recommends the following steps
for a submission of new drug products:
Step 1. Manufacturers should keep the health-
system clinical pharmacy staff informed of the
status of drugs in their pipeline. Both parties should
identify speciﬁc contacts to ensure efﬁcient
communication.
Approximately six months before product launch,
the health-system pharmacy staff should issue a for-
mal unsolicited request letter that contains a copy
of the formulary submission requirements (Table 2).
The letter should be addressed to the appropriate
company employee who can engage in health pro-
fessional-to-health professional communication, in
compliance with FDA regulations, on provision of
label and off-label information.
Step 2. Following submission of the unsolicited
request, the health-system pharmacy staff and man-
ufacturer representatives may schedule an initial
presubmission meeting. In addition to the agenda
items listed in Table 1, the two parties should estab-
lish a deadline for dossier submission based on the
anticipated review date and discuss other pertinent
issues such as commercial-in-conﬁdence data,
economic model assumptions, and availability of
spreadsheet models.
Step 3. At least two months before the product
review, the manufacturer will present one paper
copy and one electronic copy of the submission dos-
sier to the health system.
Step 4. The health-system clinical staff assigned
to the product will review the submission. Based on
the initial review, the manufacturer may be asked to
clarify certain points or submit additional informa-
tion before a formulary monograph is prepared by
the health-system staff for P & T review.
Step 5. The designated clinical pharmacists will
Table 2 Sample unsolicited request letter
[Date]
[Name of Account Manager/Medical Science Liaison]
[Name of Company]
[Address]
Dear __________:
[Organization name] has adopted the Academy of Managed Care Pharmacy’s (AMCP) Format for Formulary Submissions detailing the process and 
evidentiary requirements for the provision of clinical and economic information to support drug formulary consideration. [Organization name] 
considers this document an unsolicited request for medical, economic, and other scientiﬁc information (including any unpublished and/or 
off-label study data that are to be considered by our organization) and pharmacoeconomic modeling on all pharmaceutical products that we 
consider for formulary inclusion or as part of therapeutic class reviews. The speciﬁc details of the [organization name] request have been 
sent to you previously and are available on the [organization name] Web site ([http://www.xxx.com]).
We consider this unsolicited request to represent the desired information to accompany a formulary submission. Manufacturers should submit 
a complete dossier well before they expect the product to be considered for formulary review. Our goal is to enable all of the [organization 
name] pharmacy and therapeutics (P&T) committees to make evidence-based decisions representing good value for money when selecting 
preferred treatment options. The AMCP Format describes a standardized template for pharmaceutical manufacturers to construct and submit 
a formulary dossier. The dossier is designed to make the product evaluation process in formulary development more complete, evidence-based, 
and rational.
By submitting this request, [organization name] recognizes that conﬁdential information may be provided. [Organization name] recognizes 
the need to respect and honor commercial-in-conﬁdence information and may be willing to sign necessary conﬁdentiality agreements under 
agreed circumstances.
Please consider this letter as an unsolicited request for information required by [organization name] for [name of product or products here]. 
If you require additional information, please call _________.
Sincerely,
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prepare a detailed summary (monograph) for P & T
review. The summary presents an overview of all
data, principal arguments for and against listing the
product on formulary, and any conditions that may
apply.
Step 6. As soon as possible, health-system staff
will inform the manufacturer of the P & T commit-
tee’s recommendation. Upon request, staff may pro-
vide the manufacturer with the rationale for a
product’s denial or restriction as well as guidance
for reconsideration or appeal.
Note that establishment of a formal appeals
process is at the discretion of individual health-
care systems. State or federal law may require
public entities, such as state Medicaid agencies, the
Department of Defense, or the Veterans Adminis-
tration to have formal appeals processes in place to
deal with denials related to formulary decisions.
Periodic Review of Therapeutic Classes
Periodically, a health system will undertake reviews
of all drugs in each therapeutic class, including
drugs currently listed and those that are nonformu-
lary. The health system may ask manufacturers to
update their product dossiers with the most recent
clinical data and economic modeling information. If
P & T committee procedures include a regular ther-
apeutic class review, they should request updated
dossiers through issuance of a separate unsolicited
request letter. In addition, when a health-system
schedules a review of a new competitor product it
may ask manufacturers for an updated dossier for
products with the same or very similar clinical pro-
ﬁles. In each case, the health system should give
manufacturers as much notice as possible.
Health-System Guidelines for Manufacturers 
(Evidentiary Requirements for Formulary 
Submission Dossiers)
A complete formulary submission dossier for phar-
maceutical, biological, and vaccine products should
include the following sections: disease and product
information, supporting clinical and economic infor-
mation, cost-effectiveness and budget impact model
report, product value and overall cost, and other
supporting information such as reprints, biblio-
graphy, checklist, electronic media, and appendices.
Product Information: Format Section 1.0
Product Description (20-Page Limit): Format 
Section 1.1
Manufacturers are required to provide detailed
information about their product. They should
compare the new product with other agents com-
monly used to treat the condition, whether or not
these products are currently on the health system’s
formulary. The product description consists of
information that manufacturers traditionally incor-
porate into a product monograph or formulary kit
and includes the elements listed in Table 3.
Table 3 Product description
a. Generic, brand name, and therapeutic class of the product.
b. All dosage forms, including strengths and package sizes.
c. The National Drug Code (NDC) for all formulations.
d. A copy of the ofﬁcial product labeling/literature.
e. The AWP and WAC cost per unit size. (The [—] contract price, if available, should be included as well.)
f. AHFS or other drug classiﬁcation.
g. FDA-approved and other studied indication(s): A detailed discussion of the approved FDA indications and the date approval was granted 
(or is expected to be granted) must be included. Information on pending off-label indications and other nonlabeled uses, if available, should 
be included.
h. Pharmacology.
i. Pharmacokinetics/pharmacodynamics.
j. Contraindications.
k. Warnings/precautions.
l. Adverse effects.
m. Interactions, with suggestions on how to avoid them:
• Drug/drug
• Drug/food
• Drug/disease
n. Dosing and administration.
o. Access, e.g., restrictions on distribution, supply limitations, anticipated shortages.
p. Coprescribed/concomitant therapies, including dosages.
q. Comparison with the pharmacokinetic/pharmacologic proﬁle of other agents in the therapeutic area. The material may include a discussion 
of comparator product(s) or services for which the proposed product may be expected to substitute or replace (including drug and 
nondrug interventions). The manufacturer should present this information in tabular form.
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Place of the Product in Therapy (1- to 3-Page Limit): 
Format Section 1.2
In addition to the disease description, manufac-
turers should include characteristics of the patients
who would be treated for the condition and present
a brief summary of information from the literature
for each topic. When the manufacturer presents
information from studies, it should compile the
results in detailed evidence tables. Next, it should
attempt to generalize these ﬁndings to the popula-
tions of the health system and discuss the implica-
tions of any differences that exist between the
literature and typical practice patterns and patient
populations. When more than one disease is ad-
dressed, manufacturers are to complete the de-
scription for each separate condition. The health
system and the manufacturer should determine the
relevant treatment options for comparison during
the initial presubmission meeting. Speciﬁc disease
descriptive information should include the elements
listed in Table 4 (two- to three-page limit per
disease).
Supporting Clinical and Economic 
Information: Format Section 2.0
Summarizing Key Clinical and Economic Studies: 
Format Section 2.1
Manufacturers should submit the key clinical
and economic studies that have been conducted,
whether published or not, for clinical safety, efﬁ-
cacy, economic, and health outcomes evaluations.
They should summarize these studies in a clear, con-
cise format. The guidelines strongly encourage the
presentation of data from multiple studies in tabu-
lar form within a category. All of the elements listed
in Table 5 that apply should be included.
Published and Unpublished Clinical Study Results 
(Two-Page Limit per Study): Format Section 2.2
Manufacturers should provide summaries address-
ing items a through “m” listed in Table 5 for studies
in each of the categories listed in Table 6 (items a–
d). The manufacturer should complete evidence
tables that summarize the data. Health systems are
particularly interested in head-to-head comparison
clinical studies between the proposed product and
the principal comparators. Summaries of trial
results of key comparator products are desirable
but not required. Manufacturers should include a
discussion of important study ﬁndings and com-
ment on their implications for the patient popula-
tions represented by the requesting health system.
Systematic reviews or meta-analyses may be refer-
enced in Table 6, item “e”. Manufacturers are to
include, in the dossier appendix, a reprint of each
key study discussed or referenced.
Table 4 Disease description
a. Epidemiology and relevant risk factors
b. Pathophysiology
c. Clinical presentation
d. Approaches to treatment—principal options/practice patterns
e. A description of alternative treatment options (both drug and 
nondrug)
f. The place and anticipated uses of the proposed therapy in 
treatment (e.g., ﬁrst line)
g. The expected outcomes of therapy
h. Other key assumptions and their rationale
Table 5 Study summaries
All of the following that apply should be included:
a. Name of the clinical trial or study, location and study date
b. Trial design, randomization and blinding procedures
• Research question(s)
• Study perspective
c. Washout, inclusion and exclusion criteria;
d. Sample characteristics (demographics, number studied, disease severity, comorbidities)
• Treated population (actual or assumed)
e. Patient follow-up procedures (e.g., If an intention-to-treat design is used, were drop-outs followed and for what time period?)
• Treatment period
f. Treatment and dosage regimens
• Treatment framework
• Resource utilization classiﬁcation
• Unit costs
g. Clinical outcome(s) measures
• Outcomes evaluated
h. Other outcome measures (e.g., quality of life)
• Principal ﬁndings
i. Statistical signiﬁcance of outcomes and power calculations
j. Validation of outcomes instrument (if applicable)
k. Compliance behavior
l. Generalizability of the population treated
• Relevance to the health system’s enrolled populations
m. Publication citation(s)/references used
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In addition, manufacturers should summarize
information from all known studies on the product
in a spreadsheet format, noting which studies were
presented previously (Table 6, items a–e). Evidence
table spreadsheets of all published and unpublished
trials should follow a standard evidence table for-
mat, such as that contained in the AMCP Format’s
Appendix C, Template for P & T Monograph, and
should include the following data elements:
• Citation, if published
• Treatments
• Sample size
• Inclusion/exclusion criteria
• End points
• Statistical signiﬁcance
• Study dates
• Results
• Design
Clinical and Disease Management Intervention 
Strategies (Three-Page Limit): Format Section 2.3
Manufacturers should identify and summarize any
proposed ancillary disease or care management
intervention strategies that they intend to accom-
pany the product at launch.
Outcomes Studies and Economic Evaluation 
Supporting Data (Two-Page Limit per Study): 
Format Section 2.4
Many researchers have expressed concern over the
quality of some published economic evaluations
[17–19]. Because the focus of this portion of the
dossier is a comprehensive assessment of available
evidence, manufacturers are not restricted to a spe-
ciﬁc number of studies by the imposition of meth-
odologic standards. Nevertheless, a health system
and/or its consultants are strongly advised to judge
the merit of individual studies based on published
standards for conducting and reporting these anal-
yses [19–26].
Manufacturers should provide summaries
addressing items a through m, as described previ-
ously under “Summarizing Key Clinical and Eco-
nomic Studies: Format Section 2.1,” for all studies
in each of the categories listed in Table 7. Health
systems are particularly interested in head-to-head
comparison studies between the proposed product
and the principal comparators. Analyses that focus
on actual outcomes rather than intermediate end
points are preferred. Although not required, manu-
facturers are encouraged to supply summaries of
principal trial results of key comparator products
when these data are referenced or used in economic
models. Manufacturers should discuss important
study ﬁndings and comment on their implications
for the health system’s patient population. Manu-
facturers are to include, in the dossier appendix, a
reprint of each key study discussed or referenced.
Modeling Report (20-Page Limit): Format 
Section 3.0
Model Overview: Format Section 3.1
Properly constructed economic and budget impact
models can combine treatment effectiveness, the
resources consumed (and costs) by each treatment
process, and a measure of uncertainty in any esti-
mates. The goal is to project the health and eco-
nomic consequences of the health-system formulary
changes. Models developed in this manner can aid
decisions regarding the addition of a new product to
the formulary, help deﬁne a product’s speciﬁc role,
and assist in creating benchmarks against which
health systems can measure future product perform-
ance. Properly constructed economic and budget
impact models should depict the elements detailed
in Table 8.
Manufacturers should base their analysis on sci-
entiﬁcally appropriate clinical trial, epidemiologic,
and economic data. As mentioned earlier, the health
Table 6 Clinical study categories
a. Pivotal safety and efﬁcacy trials (usually no more than one page 
per study + evidence table).
b. Prospective effectiveness (e.g., large simple) trials (usually no 
more than one page per study + evidence table).
c. Additional prospective studies examining other noneconomic 
end points such as health status measures and quality of life. If the 
instruments utilized in these studies are supported by previous 
validation and reliability studies, also reference these studies (no 
more than one page per study).
d. Retrospective studies (no more than one page per study + 
evidence table).
e. Review articles and meta-analyses. Place particular emphasis on 
the inclusion and exclusion criteria and main outcome 
measure(s) for studies analyzed.
Table 7 Outcomes and economic study categories
a. Prospective cost-efﬁcacy studies (no more than two pages per 
study + evidence table).
b. Prospective cost-effectiveness studies trials (no more than two 
pages per study + evidence table).
c. Cross-sectional or retrospective costing studies, treatment 
pattern studies, or economic evaluations (no more than two 
pages per study + evidence table).
d. Review articles.
e. Spreadsheet of all published and unpublished economic 
evaluations utilizing the format speciﬁed in section 2.2, noting 
which studies were presented previously.
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system should be able to modify the model to better
reﬂect practice patterns in their enrolled population.
For the analysis and model to be realistic, it may be
necessary to include data from the health system,
e.g., demographic data. Data derived from expert
panels are not generally acceptable, especially for
key clinical and treatment pattern variables. Never-
theless, this approach may be understandable for
other variables where estimates are not available
through literature, databases, trials, or other nor-
mal sources.
The model framework should consider recom-
mendations published by the Panel on Cost-
Effectiveness in Health and Medicine convened
by the US Public Health Service [3]. Although the
AMCP Format does not propose a standard model
approach, those preparing the product dossiers
should always follow good modeling practices. The
authors of AMCP’s Format found that models have
certain desirable qualities. These qualities are listed
in Table 9 and are in no way meant to proscribe
model development or impede good scientiﬁc
design. Rather, the list is intended to provide some
guidance to the manufacturer as to those elements
of an economic model that are desirable to a health
system’s evaluators.
Parameter Estimates for Models: Format Section 3.2
Randomized, controlled efﬁcacy studies are re-
quired for licensing and registration. These data
comprise the foundation for FDA approval, labeled
indications, and marketing. Health systems recog-
nize that manufacturers must conduct these studies
for the FDA. In addition, health systems are aware
that the results observed in randomized trials are
likely to represent optimal effects and are difﬁcult to
generalize to populations because of patient selec-
tion and the close oversight given subjects in clinical
trials.
In general, the best quantitative estimates of
clinical effectiveness are required, with uncertainty
in the estimate(s) handled analytically via sensitivity
analysis. Thus, where possible, feasible, and scien-
tiﬁcally plausible, scientists preparing the economic
model are encouraged to attempt transformation of
efﬁcacy results into effectiveness parameters. This
may involve inclusion of an adherence parameter
into the model or may involve the creative use
of retrospective data. Documentation and clear
description of the method will be necessary for a
health system’s staff to evaluate the validity of this
approach.
Manufacturers should consider translation of
claims from an efﬁcacy to an effectiveness context
when the model’s treatment period extends beyond
that represented by the clinical trial; outcomes sup-
ported by the trial are intermediate or surrogate in
nature; and compliance, dosing, comorbid condi-
tions, and the population of interest (e.g., children,
elderly) are expected to differ from the efﬁcacy trial
data.
Poor adherence to therapy, especially for chronic
conditions, can affect manufacturer claims if they
base them exclusively on carefully monitored clini-
Table 8 Scope of economic model report
Economic and budget impact analyses should depict the following:
a. Disease or condition, patient population, natural history, clinical course, and outcomes.
b. Primary treatment options and the treatment process for each option. Each process of treatment utilizing a speciﬁc product or other 
intervention follows a clinical pathway. If the health system employs a treatment guideline for this condition, this framework should be 
followed. Alternative clinical pathways presented by the manufacturer may also be considered.
c. Patient population eligible for treatment.
d. Product and other medical resources used when following clinical pathway (include treatments for complications related to treatment).
e. Costs of product and other medical resources consumed within each clinical pathway.
f. Outcomes of therapy for each clinical pathway, including expected proportion of treatment failures and mean or median time to failure, if 
known. These outcomes can be broadly and uniquely deﬁned by the manufacturer and can be modeled from other data sources. The 
manufacturer should address the relevance of the selected outcomes measure and generate both baseline and projected outcome impact 
assessments.
g. Incremental cost and outcomes analysis presented either in cost/consequences tables or as cost-effectiveness ratios.
h. Time horizon for expected costs and outcomes.  Suggested time horizons include 1 year, 5 years, and over the course of the disease. The 
exact time horizon used will depend on the natural course of the disease. In some cases, multiple time horizons might be appropriate.
In addition, the manufacturer is requested to:
i. Separate the volume of resources utilized and the unit costs for each resource.
j. Perform sensitivity analyses on pivotal estimates and assumptions and display a one-way sensitivity analysis of all variables in a tornado 
diagram.
k. Consult with the health-system staff in the early stages of model development to ensure the incorporation of appropriate comparator 
products and end points.
l. Present the following information in tabular form: data and sources, assumptions, total resource utilization, total costs, total effectiveness, 
incremental costs, and incremental effectiveness. Measures of total and incremental effectiveness should incorporate natural units (e.g., 
clinically important events avoided) as well as quality-adjusted survival when possible.
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cal efﬁcacy trials. All claims promotional or other-
wise made for new products should state clearly the
assumptions concerning patient adherence. Manu-
facturers should provide documentation of antici-
pated adherence patterns from populations similar
to the treatment populations of the requesting
health system, if available. This may be more plau-
sible for manufacturers who have launched prod-
ucts in other countries before the US introduction.
Perspective, Time Horizon, and Discounting: 
Format Section 3.3
The primary analysis should take the payer perspec-
tive. Manufacturers are welcome to take a societal
perspective analysis as a secondary evaluation. The
analytic model should consider a time horizon that
is appropriate to the disease being studied and
reﬂect the decision-making and ﬁnancial and budget
constraints of the health system. When appropriate,
adjustment for the time preference should be incor-
porated and should follow US Public Health Service
Panel recommendations [3].
Analyses: Format Section 3.4
Analyses should follow accepted approaches for
economic models. Transparency and clarity of pre-
sentation make for understandable modeling exer-
cises. The requesting health-system staff needs to be
able to understand all steps in the modeling process,
so researchers are encouraged to spend time think-
ing about clarity and transparency of results. All
assumptions must be presented and justiﬁcation
should be attempted.
A tornado diagram with a comprehensive (all
variables) one-way sensitivity analysis is highly
recommended. Base-case and other appropriate
sensitivity analyses also are recommended. Conﬁ-
dence interval determination, best/worse-case sce-
nario analyses, and net-beneﬁt and acceptability
curve estimation are allowable as necessary and
appropriate.
When a product is to be used in the treatment of
more than one disease, its impact should be mod-
eled for each approved indication, unless a reason-
able case can be made for a single model. Because of
the complexity involved in constructing a model
that simultaneously addresses several indications,
manufacturers are advised to prepare a separate
model for each condition.
Presentation of Model Results: Format Section 3.5
Manufacturers should present model results as
follows:
• Present disaggregated results (cost-consequence
presentation style) before viewing incremental
cost-effectiveness ratios. These data are more
easily understood and interpretable by health-
system formulary committees.
• Present costs as the total medical and pharmacy
costs of introducing the new product and then
disaggregate them into various resource com-
ponents including drug costs.
• Estimates must include the cost of any addi-
tional resources associated with implementing
the therapy (e.g., disease management).
Table 9 Desirable qualities of economic models
Structure
a. A transparent disease progression model with an appropriate time horizon for a health system.
b. Treatment pathways that are relevant to the formulary decision and correspond to nationally recognized or health-system treatment 
guidelines. To help illuminate the proposed treatment pathways, the manufacturer is encouraged to provide decision trees.
c. Usual clinical practice, including comparator products that are relevant to the health system, is included in the model.
d. Mathematics and calculations included in the model are accurate and available for inspection.
e. Allowance for analysis of relevant subpopulations (age, sex, comorbidities) where applicable.
f. An interactive model that allows the health system to incorporate its own data (membership size, prevalence rates, cost estimates, etc.) 
or, if requested, use default data, such as national norms.
Data
a. Sources of data are clearly deﬁned and from the most recent studies.
b. Data have been interpreted and accurately incorporated into the model.
c. Uncertainty is deﬁned, especially for key variables.
d. Linkages between intermediate and longer-term end points are valid and based on reasonable scientiﬁc evidence.
e. Assumptions that drive the model are clearly identiﬁed.
Results/output
a. Outcomes need to be relevant to the health system’s formulary decision.
b. Incremental analyses of both health effects and costs.
c. Results are veriﬁable and traceable back to the inputs.
d. Uncertainty in model and data tested in a reasonable fashion and reported.
e. A tornado diagram depicting the results of a comprehensive (on all variables) one-way sensitivity analysis.
f. Results presented in such a fashion that facilitates incorporation into drug reviews and monographs.
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• Present health effects in disaggregated form
before inclusion in a ratio.
• Show sensitivity analyses in tabular or graphi-
cal form (tornado diagram), with the base-case
results displayed alongside.
• Clearly present factors that drive the cost and
cost-effectiveness results, for example, tornado
diagrams.
Exceptions: Format Section 3.6
A pre-existing model developed for another health
system or for another country may eliminate the
need to develop a new model for a particular sub-
mission. A model based on national norms may also
be acceptable provided the manufacturer submits it
in such a manner, such as a spreadsheet, that the
health system can either use the default values or
insert its own. To be acceptable, the existing model
should follow the general framework described in
this document and must be able to demonstrate the
systemwide impact of introducing the product to
the health-system formularies. It is the manufac-
turer’s responsibility to justify the adequacy of pre-
existing models. Developing a model that can be
adaptable and allow the health system to make
changes in multiple elements will greatly enhance
this process.
Product Value and Overall Cost 
(Two-Page Limit): Format Section 4.0
This section of the submission requirements repre-
sents the principal opportunity for a manufacturer
to communicate the value of its product to the
requesting health-care system. The manufacturer
should brieﬂy summarize the information presented
previously, state the expected per-unit product cost,
and estimate the total pharmacy expenditures for
the product. Based on this information, the manu-
facturer should articulate a value argument to jus-
tify these expected expenditures for this product in
the context of its anticipated effects on the clinical
and other outcomes and the economic consequences
for the health-care system and its clients and mem-
bers. This process of redeﬁning the product’s value
allows both parties to move beyond mere cost con-
tainment to focus on optimizing drug utilization in
an environment of limited resources.
Supporting Information: Format Section 5.0
References Contained in Dossiers: Format Section 5.1
A manufacturer’s submissions should list and pro-
vide copies of all key clinical and pharmaco-
economic references made in sections 2 and 3.
Economic Model Media: Format Section 5.2
In addition to the written report, the manufacturer
must provide a transparent, unlocked copy of the
model without the graphical interface on a 3.5-inch
disk or CD ROM as a Microsoft ExcelTM work-
book, an ASCII tab-delimited ﬁle, or an alternative
format that is acceptable to the health system or its
consultants and the manufacturer. The model
should be transparent, i.e., designed to allow staff
or consultants to investigate the assumptions and
calculations, and to perform independent sensitivity
analyses by varying individual parameters. The
health-care system will retain product models for
internal analyses and will not release them to any
other party unless the manufacturer and health-care
system reach an agreement to the contrary before
submission. Articles and manuscripts that support
the development and reporting of the model are to
be attached as appendices.
Formulary Submission Checklist: Format Section 5.3
Manufacturers should provide a completed for-
mulary submission checklist (Table 10) with each
submission and provide a brief explanation for all
missing data.
Barriers to Adoption
Certainly, adoption of the AMCP Format requires a
commitment of resources by both health systems
and manufacturers. Lack of human, IT, and ﬁnan-
cial resources to support the process within the plan
including support of senior management and the P
& T committee is one of the principal barriers to
implementation of the Format process. Other bar-
riers to implementation include:
• Lack of expertise in analyzing clinical and
health outcomes studies and pharmacoeco-
nomic models.
• The misconception that the Format process is
merely a tool for presentation of a pharmac-
oeconomic model.
• Mistrust of any economic models prepared by
pharmaceutical manufacturers.
• Commitment to a decision-making process
based primarily on product cost and rebates
(i.e., silo mentality).
• Manufacturer reliance on marketing and pro-
motions to move market share.
• Concern over FDA scrutiny.
• Concern about conﬁdentiality of propriety
information contained in dossiers.
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P & T committees could take the easy path and
simply put new or expensive drugs on the third tier
of their beneﬁt structure and avoid the cost and
effort of the AMCP Format process. One of the key
purposes of a formulary is to make medications that
produce the best positive outcomes at reasonable
costs (i.e., those drugs that show value), available to
a plan’s membership. The AMCP Format authors
designed the guidelines speciﬁcally for that purpose.
They allow a health system and its P & T committee
to determine the clinical beneﬁts of a drug, verify
any cost savings the drug may generate, and deter-
mine the overall cost consequences to their health
system.
If a health system simply puts a new or expensive
medication on the third tier, two negative conse-
quences could arise. First, despite its high cost, the
medication may have signiﬁcant clinical value. Pro-
viding appropriate incentives for its use could ulti-
mately improve health and possibly lower overall
health-care costs. For example, health systems com-
monly place preferred brand name products in the
second copayment tier. For brand name products
with no generic equivalents that are known to offer
signiﬁcant clinical and economic beneﬁt for the
health system in terms of reduced morbidity, mor-
tality, and reduced hospitalizations and emergency
department visits, it may make more sense to add
the product to the ﬁrst tier, generally reserved for
generic products. By simply choosing to place the
most expensive products on the third tier, a plan can
in effect create a disincentive for their members
to use them, resulting in missed opportunities to
improve the health outcomes for individuals and
groups of patients. Second, automatically putting a
medication on the third tier denies the P & T com-
mittee or other decision-making body the opportu-
nity to fully assess the clinical and economic impact
of a product on a health system’s patient popula-
tion. Paying for a drug that has little or no value can
result in unforeseen dire consequences for patients
and health systems.
Conclusion
The persistent backlash against managed care can
be readily attributable to an American culture that
is unwilling to accept limits. Writing in Health
Affairs in 1998, Daniels and Sabin stated, “To
change that culture requires a concerted effort at
Table 10 Manufacturer’s formulary submission checklist
A. Submission process
 A.1. Have you met with health-system staff to review the submission process?  Yes  No
 A.2. Have you agreed to the submission date?  Yes  No
 A.3. Have you requested estimates to identify baseline characteristics of the populations represented by the 
health system?
 Yes  No
 A.4. Have you included an explanation for any missing data? (Check yes if N/A)  Yes  No
 A.5. Have you submitted a copy of the dossier in both paper and electronic form?  Yes  No
B. Product information
 B.1. Has a product description been provided for the product?  Yes  No
 B.2. Has a list of approved indications been given for the product?  Yes  No
 B.3. Has the place of this product in therapy been given for each indication?  Yes  No
 B.4. Have copies been provided of treatment guidelines for this product?  Yes  No
 B.5. Have intermediate and ﬁnal outcomes of therapy for this product been listed?  Yes  No
 B.6. Have you listed any coprescribed drugs for this product by indication?  Yes  No
 B.7. Have you identiﬁed the comparator drugs for this product by indication?  Yes  No
C. Supporting clinical information
 C.1. Have you identiﬁed all relevant clinical and other studies for the product and its comparators?  Yes  No
 C.2. Are copies of all summarized studies included in the submission package?  Yes  No
 C.3. Have you provided an electronic spreadsheet summary of all studies identiﬁed using the requested format?  Yes  No
 C.4. Have you included all relevant nonexperimental studies for the product?  Yes  No
 C.5. Have you provided an electronic spreadsheet summary of all nonexperimental studies using the requested 
format?
 Yes  No
D. Supporting economic information
 D.1. Have you identiﬁed all relevant pharmacoeconomic (PE) studies for the product?  Yes  No
 D.2. Are copies of all summarized studies included in the submission package?  Yes  No
 D.3. Have you justiﬁed the relevance of these PE studies for this population?  Yes  No
 D.4. Have you provided an electronic spreadsheet summary of the PE studies?  Yes  No
 D.5. Will a disease or care management strategy be employed with the introduction of this product?  Yes  No
 D.6. Is documentation on this intervention program included in the submission?  Yes  No
E. Economic model
 E.1. Are the model structure, data, and assumptions transparent and clearly presented for a noneconomist 
reader?
 Yes  No
 E.2. Is an unlocked spreadsheet version of the model included with the submission?  Yes  No
 E.3. Are the results presented in a style suitable for the health system’s formulary committee evaluation?  Yes  No
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education, and education requires openness about
the rationales for managed care plan’s decisions”
[27]. By adhering to careful and thoughtful deci-
sion-making processes that provide the rationales
for limits, health care systems will be able to show,
over time, that “arguably fair decisions are being
made and that those making them have established
a procedure we should view as legitimate” [27]. The
AMCP and FMCP believe that the AMCP Format
is a tool that will help health systems establish a
record of commitment to rational decision making
thus gaining the conﬁdence of patients, clinicians,
and members. There is a growing movement toward
the use of the AMCP Format for Formulary Sub-
missions as an essential tool to evaluate medica-
tions, but its use requires thoughtful consideration.
The successful completion of Version 2.0 of the AMCP
Format for Formulary Submissions would not have
been possible without the sage advice and constructive
comments of the AMCP Format Revision Committee:
Kerri Chitwood-Dagner, PharmD, BS Pharm, National
Pharmacy Director, Great-West Life; Joseph A. Gricar,
MS, Regional Outcomes Research Manager, Pharmacia
Corporation; Dell Mather, PharmD, BS Pharm, Senior
Director, Pharmacotherapy Assessment and Policy, Prime
Therapeutics, Inc.; Marsha Moore, MD, MBA, Senior
Vice President, Medical Affairs, AdvancePCS; Pete Penna,
PharmD, Partner, Formulary Resources, LLC; and Nancy
E. Stalker, PharmD, Vice President of Pharmacy Services,
BlueShield of California. The Academy and Foundation
are deeply indebted to Dr Sean Sullivan, the principal
author of Version 2.0, for his continuing passionate sup-
port for the AMCP Format and his tireless devotion to
evidence-based decision making.
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Appendix 1
Terms and deﬁnitions
Dossier:  A detailed report (in paper and electronic
form) for each product submitted by the manu-
facturer for consideration that contains; 1) clini-
cal and economic data from published and
unpublished studies; and 2) a disease-based eco-
nomic model to project the potential impact that
introducing the product would have on health
and economic consequences occurring across the
entire system.
Effectiveness:  The actual effects of treatment by
the drug under “real-life” conditions (patients
not always remembering to take their doses,
physicians often not prescribing the lowest
FDA-recommended doses, side effects not all
controlled, etc.). “Head-to-head” effectiveness
studies with similar medications are preferable.
Efﬁcacy:  The potential effects of treatment by the
drug under optimal circumstances (e.g., patients
all taking their doses at the right times, physicians
prescribing FDA-recommended doses, side effects
appropriately monitored, etc.). Efﬁcacy studies
are typically the foundation of new drug sub-
missions to the FDA. Studies that compare the
efﬁcacy of similar drugs, rather than efﬁcacy
compared to placebo, are preferable.
Formulary:  A periodically updated list of medica-
tions, related products, and information, repre-
senting the clinical judgment of physicians,
pharmacists, and other experts in the diagnosis
and/or treatment of disease and promotion of
health.
Formulary system:  An ongoing process whereby
a health-care system, through its physicians,
pharmacists, and other health-care professionals,
establishes policies on the use of drugs, related
products, and therapies and identiﬁes drugs,
related products, and therapies that are the most
medically appropriate and cost-effective to best
serve the health interests of the patient popula-
tions of the health systems it represents.
Modeling:  A quantitative modeling method used to
estimate the impact of formulary changes on: 1)
potential health outcomes; and 2) total costs of
drug and medical care in a population. One pos-
sible use of cost and outcomes modeling, for
example, is to extrapolate trial-based efﬁcacy
data into effectiveness and cost-effectiveness end
points of relevance to health-care systems. Cost
and outcomes impact data from models can then
be used to assess the health and overall ﬁscal con-
sequences of formulary changes.
